Table 1 Demographic, clinical and cytogenetic characteristics of 1181 patients with newly diagnosed multiple myeloma stratified by the number of cytogenetic high-risk abnormalities (HRA)
0 HRA n=884 | 1 HRA n=262 | 2 HRA n=35 | |
|---|---|---|---|
Men (n (%)) | 540 (61) | 147 (56) | 21 (60) |
Age at diagnosis (years) | 65 (28–95) | 65 (32–91) | 63 (48–80) |
Follow-up (years) | 3.3 (0.1–10.8) | 2.5 (0.2–10.7) | 2.6 (0.1–10.0) |
Overall survival (years) | 8.3 (6.7–8.9) | 4.9 (3.7–5.5) | 3.0 (1.7–3.8) |
ISS stage at diagnosis (n (%)) | |||
I | 270 (31) | 66 (25) | 5 (14) |
II | 354 (40) | 99 (38) | 11 (32) |
III | 260 (29) | 97 (37) | 19 (54) |
Overall survival by ISS stage (years (95% CI)) | |||
I | 9.2 (8.6–NR) | NR (3.5–NR) | 6.5 (1.1–NR) |
II | 8.5 (6.6–8.9) | 4.9 (3.7–5.8) | 3.5 (1.0–NR) |
III | 5.0 (4.2–5.6) | 3.7 (2.1–5.3) | 2.6 (0.4–3.6) |
Cytogenetic high-risk abnormalities (n (%)) | |||
del(17p) | 0 (0) | 135 (52) | 35 (100) |
High-risk translocation | 0 (0) | 127 (48) | 35 (100) |
t(4;14) | 0 (0) | 87 (33) | 23 (66) |
t(14;16) | 0 (0) | 32 (12) | 12 (34) |
t(14;20) | 0 (0) | 8 (3) | 0 (0) |
First-line treatment (n (%)) | |||
Immunomodulator | 483 (55) | 96 (37) | 11 (31) |
Proteasome inhibitor | 294 (33) | 111 (42) | 11 (31) |
Both | 107 (12) | 55 (21) | 13 (38) |
Upfront ASCT | 348 (40) | 91 (35) | 11 (31) |
